NRSN: רווח למניה בשנים עשר החודשים האחרונים NeuroSense Therapeutics

The TTM net income per share on the GURU.Markets time chart reflects the price action of NeuroSense Therapeutics (NRSN), a biopharmaceutical developer of ALS therapies investing in RNA regulation. The business model relies on outsourcing production and trials to minimize capital expenditures. The value of 0.00 shapes the current metric, while the cohesive management team led by Alon Ben-Nun prepares the final test results for publication.

NeuroSense Therapeutics (NRSN) focuses on developing therapies for amyotrophic lateral sclerosis, leveraging a highly qualified scientific staff. This indicator calculates the total annual net income divided by the total number of shares, neutralizing the effect of equity dilution. It is critical for investors to track this metric to assess the real business efficiency relative to market value. The trend of this metric allows for the timely detection of how borrowing costs impact capitalization. Analyzing the rolling year earnings per share helps avoid investment stagnation.